GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » J.Molner AS (OTSE:MOLNR) » Definitions » Tax Provision

J.Molner AS (OTSE:MOLNR) Tax Provision : €0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is J.Molner AS Tax Provision?

J.Molner AS's tax provision for the six months ended in Dec. 2023 was €0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.


J.Molner AS Tax Provision Historical Data

The historical data trend for J.Molner AS's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

J.Molner AS Tax Provision Chart

J.Molner AS Annual Data
Trend Dec21 Dec22 Dec23
Tax Provision
- - -

J.Molner AS Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Tax Provision - - - - -

J.Molner AS Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


J.Molner AS (OTSE:MOLNR) Business Description

Traded in Other Exchanges
N/A
Address
Akadeemia tee 21/5, Harju maakond, Tallinn, EST, 12618
J.Molner AS is an Estonia-based company. The company is engaged in research and development in the field of biotechnology. The activities of the Company are divided into two fields: 1) Chemistry analytical and development services for third parties; 2) Development of the Company's own line of generic pharmaceuticals.

J.Molner AS (OTSE:MOLNR) Headlines

No Headlines